BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brummelhuis ISG, Wimper Y, Witjes-van Os HGJM, Arends TJH, van der Heijden AG, Witjes JA. Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. Cancers (Basel) 2021;13:377. [PMID: 33498535 DOI: 10.3390/cancers13030377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Brummelhuis ISG, Crezee J, Witjes JA. Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer. Int J Hyperthermia 2023;40:2157498. [PMID: 36755433 DOI: 10.1080/02656736.2022.2157498] [Reference Citation Analysis]
2 Vartolomei MD, Ferro M, Roth B, Teoh JY, Gontero P, Shariat SF. Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update. Curr Opin Urol 2022. [PMID: 35749398 DOI: 10.1097/MOU.0000000000001010] [Reference Citation Analysis]
3 Van Hattum JW, Scutigliani EM, Helderman RFCPA, Zweije R, Rodermond HM, Oei AL, Crezee J, Oddens JR, De Reijke TM, Krawczyk PM. A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer. Sci Rep 2022;12:7017. [PMID: 35488115 DOI: 10.1038/s41598-022-11016-y] [Reference Citation Analysis]
4 Barki C, Rahmouni HB, Labidi S. Reasoning about bladder cancer treatment outcomes using clinical trials within a knowledge-based clinical evidence approach. Procedia Computer Science 2022;196:631-639. [DOI: 10.1016/j.procs.2021.12.058] [Reference Citation Analysis]
5 Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM, Díaz-Goizueta FJ, Del Álamo JF, Gonzalo V, Montero J, Sousa-Escandón A, León J, Pontones JL, Delgado F, Adriazola M, Pascual Á, Calleja J, Ruano A, Martínez-Piñeiro L, Angulo JC. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J Clin Med 2021;10:5105. [PMID: 34768625 DOI: 10.3390/jcm10215105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Roumiguié M, Black PC. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro. Eur Urol Focus 2021:S2405-4569(21)00234-0. [PMID: 34593355 DOI: 10.1016/j.euf.2021.07.018] [Reference Citation Analysis]
7 Zhang YS, Li XJ, Zhang YH, Hu TC, Chen WZ, Pan X, Chai HY, Wang X, Yang YL. Carbon ion radiotherapy for bladder cancer: A case report. World J Clin Cases 2021; 9(26): 7833-7839 [PMID: 34621834 DOI: 10.12998/wjcc.v9.i26.7833] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Crezee J, Franken NAP, Oei AL. Hyperthermia-Based Anti-Cancer Treatments. Cancers (Basel) 2021;13:1240. [PMID: 33808948 DOI: 10.3390/cancers13061240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]